Literature DB >> 19364702

Local surgical, ablative, and radiation treatment of metastases.

Robert D Timmerman1, Costas S Bizekis, Harvey I Pass, Yuman Fong, Damian E Dupuy, Laura A Dawson, David Lu.   

Abstract

Because local therapies directed toward a specific tumor mass are known to be effective for treating early-stage cancers, it should be no surprise that there has been considerable historical experience using local therapies for metastatic disease. In more recent years, increasing interest in the use of local therapy for metastases likely has arisen from improvements in systemic therapy. In the absence of effective systemic therapies, such local treatments were often considered futile given both the difficulty in eliminating all sites of identifiable metastatic disease as well as realities regarding the rapid natural history of uncontrolled tumor dissemination. However, with a higher likelihood of patients surviving longer after effective systemic therapy, even if not cured, the goal of the eradication of residual metastases via potent local therapies can be rationalized. However, this rationalization should be evidence-based so as to avoid harming patients for no established benefit. Although surgical metastectomy remains the most common and first-line standard among local therapies, nonsurgical alternatives, including thermal ablation and stereotactic body radiotherapy, have become increasingly popular because they are generally less invasive than surgery and have demonstrated considerable promise in eradicating macroscopic tumor. Rather than eliminating the need for local therapies, improvements in systemic therapies appear to be increasing the prudent utilization of modern local therapies in patients presenting with more advanced cancer. (c) 2009 American Cancer Society, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19364702     DOI: 10.3322/caac.20013

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  52 in total

1.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

Review 2.  Melanoma: from patient presentation to pathology report.

Authors:  Omar W Jassim; Anne C Lind
Journal:  Mo Med       Date:  2010 Mar-Apr

3.  Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature.

Authors:  Concetta Elisa Onesti; Daniela Iacono; Silvia Angelini; Salvatore Lauro; Marco Mazzotta; Mario Alberto Occhipinti; Raffaele Giusti; Paolo Marchetti
Journal:  Transl Lung Cancer Res       Date:  2016-12

4.  Hypofractionated stereotactic radiotherapy for oligometastatic patients: developing of a response predictive model.

Authors:  Barbara Diletto; Nicola Dinapoli; Silvia Chiesa; Gian Carlo Mattiucci; Vincenzo Frascino; Carmelo Anile; Cesare Colosimo; Vincenzo Valentini; Mario Balducci
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

5.  Evaluation of carcinoembryonic antigen (CEA) density as a prognostic factor for percutaneous ablation of pulmonary colorectal metastases.

Authors:  Ya Ruth Huo; Derek Glenn; Winston Liauw; Mark Power; Jing Zhao; David L Morris
Journal:  Eur Radiol       Date:  2016-05-10       Impact factor: 5.315

6.  SonoKnife: feasibility of a line-focused ultrasound device for thermal ablation therapy.

Authors:  Duo Chen; Rongmin Xia; Xin Chen; Gal Shafirstein; Peter M Corry; Robert J Griffin; Jose A Penagaricano; Ozlem E Tulunay-Ugur; Eduardo G Moros
Journal:  Med Phys       Date:  2011-07       Impact factor: 4.071

Review 7.  Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.

Authors:  Jianmin Xu; Xinyu Qin; Jianping Wang; Suzhan Zhang; Yunshi Zhong; Li Ren; Ye Wei; Shaochong Zeng; Deseng Wan; Shu Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-28       Impact factor: 4.553

8.  Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma.

Authors:  Davide Franceschini; Ciro Franzese; Fiorenza De Rose; Pierina Navarria; Giuseppe R D'Agostino; Tiziana Comito; Angelo Tozzi; Maria C Tronconi; Lorenza Di Guardo; Michele Del Vecchio; Marta Scorsetti
Journal:  Br J Radiol       Date:  2017-07-14       Impact factor: 3.039

Review 9.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

10.  Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience.

Authors:  Pierluigi Bonomo; Lorenzo Livi; Andrea Rampini; Icro Meattini; Benedetta Agresti; Gabriele Simontacchi; Fabiola Paiar; Monica Mangoni; Ivano Bonucci; Daniela Greto; Laura Masi; Raffaella Doro; Livia Marrazzo; Giampaolo Biti
Journal:  Radiol Med       Date:  2013-05-28       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.